Global Osteoporosis Market to Reach US$ Billion by 2033 – Renub Research

Osteoporosis Drugs Market is expected to reach US$ 26.70 billion by 2033 from US$ 18.18 billion in 2024, with a CAGR of 4.36% from 2025 to 2033.

renubresearch

Jul 11, 2025 - 18:26

Aging Population, Fracture Risks, and Drug Innovations Drive Market Growth

Renub Research predicts that the Global Osteoporosis Market will reach US$ % from 2025 to 2033. This remarkable growth is driven by an aging global population, the rising prevalence of osteoporosis-related fractures, advances in diagnostic imaging, and new-generation biologic therapies.

Osteoporosis, often called the "silent disease," weakens bones and increases fracture risk. It affects both men and women, but postmenopausal women are especially vulnerable due to the sudden drop in estrogen levels. With growing global awareness, improved access to healthcare, and technological developments, the osteoporosis treatment landscape is transforming rapidly.

Aging Demographics Propel Osteoporosis Prevalence Worldwide

One of the primary drivers behind the rapid market growth is the increasing elderly population. According to the World Health Organization (WHO), the global population aged 60 years and older is expected to reach 2.1 billion by 2050. Age is the most significant risk factor for osteoporosis as bones naturally become weaker over time due to lower calcium and mineral density.

This demographic shift is especially prominent in regions like North America, Europe, Japan, and China, where life expectancy is rising. As a result, there is an increased focus on preventive care, early diagnosis, and effective pharmacological management to avoid the high costs and complications associated with osteoporotic fractures.

Fracture Burden Highlights the Economic Impact

Osteoporotic fractures, particularly hip, vertebral, and wrist fractures, place a tremendous burden on public health systems and caregivers. Hip fractures are particularly devastating, leading to prolonged disability, higher mortality, and costly rehabilitation. According to various studies, over 8.9 million osteoporotic fractures occur annually worldwide, or approximately one every three seconds.

These alarming statistics underscore the urgency for early intervention and long-term management. Governments and healthcare providers are increasingly prioritizing osteoporosis screening and treatment as part of aging and public health strategies.

Market Segmentation: By Drug Type, Route of Administration, and End User

? Drug Type

Bisphosphonates (e.g., alendronate, risedronate) have long been the first-line treatment for osteoporosis due to their ability to reduce bone resorption.
Selective Estrogen Receptor Modulators (SERMs) such as raloxifene are widely used among postmenopausal women.
Parathyroid Hormone Analogues like teriparatide promote bone formation and are recommended for high-risk cases.
Monoclonal Antibodies, including denosumab, are rapidly gaining popularity for their potent antiresorptive effect and ease of use.
Calcitonin and Calcium & Vitamin D supplements support bone health, especially in combination therapies.

? Route of Administration

Oral medications are preferred due to convenience, especially for maintenance therapies.
Injectable options like denosumab (Prolia) or romosozumab (Evenity) offer better compliance and targeted delivery in patients with severe osteoporosis.

? End Users

Hospitals account for a significant share due to their role in fracture treatment, diagnosis, and infusion services.
Specialty Clinics and ambulatory care centers are increasingly utilized for injectable biologics and follow-ups.
Retail pharmacies play a crucial role in the distribution of oral osteoporosis drugs, especially in emerging markets.

Technological Advancements in Diagnosis and Risk Assessment

Diagnostic innovation is also driving the osteoporosis market. Dual-Energy X-ray Absorptiometry (DEXA) scans remain the gold standard for bone mineral density (BMD) testing. However, new tools like quantitative CT, FRAX score calculators, and AI-based bone health platforms are enabling physicians to better assess risk and tailor treatment.

Mobile health platforms and telemedicine are also improving patient compliance and monitoring, especially in remote areas.

Regional Insights: North America Leads, Asia-Pacific Rising Fast

? North America

North America holds the largest market share owing to:

High awareness levels
Strong healthcare infrastructure
Favorable reimbursement policies
Early adoption of biologics like denosumab and romosozumab

The United States is at the forefront, driven by an aging baby boomer population, national osteoporosis screening programs, and a proactive patient community.

? Europe

Europe also represents a mature market for osteoporosis treatment, particularly in Germany, the UK, France, and Italy. Public healthcare systems support early diagnosis and long-term management, while drug access is facilitated through national formularies.

? Asia-Pacific

The Asia-Pacific osteoporosis market is expected to grow at the fastest CAGR during the forecast period. Countries such as China, Japan, South Korea, and India are experiencing a surge in elderly population and osteoporotic cases. Increasing urbanization, sedentary lifestyles, and low calcium diets contribute to higher risk, while expanding healthcare infrastructure and rising disposable income fuel demand for advanced treatments.

? Latin America, Middle East & Africa

While currently at a nascent stage, these regions offer immense potential due to improving access to healthcare, growing awareness, and government investments in public health initiatives.

Competitive Landscape: Leading Companies and Strategic Developments

The global osteoporosis market is highly competitive with several global and regional players focused on biologics innovation, lifecycle management of existing drugs, and geographic expansion.

Key Market Players:

Amgen Inc. (Prolia, Evenity)
Eli Lilly and Company
Merck & Co., Inc.
Pfizer Inc.
Novartis AG
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline
UCB Pharma
Teva Pharmaceuticals
Mylan N.V.

These companies are pursuing R&D investments, strategic partnerships, and mergers to strengthen their portfolios. Several biosimilars are also entering the market, particularly for denosumab, further increasing accessibility and competition.

Market Outlook: Future Trends in Osteoporosis Treatment

The osteoporosis market is evolving toward personalized medicine, predictive analytics, and combination therapies. Key trends shaping the future include:

Biologic Therapies: With growing acceptance of monoclonal antibodies and anabolic drugs, biologics will lead innovation.
AI-Powered Risk Assessment: Integration of digital health tools for BMD monitoring and predictive modeling will enhance prevention strategies.
Preventive Care Focus: Calcium-rich nutrition, fall prevention programs, and lifestyle interventions will play a bigger role in public health policy.
Biosimilars Boom: With patents expiring, biosimilar entries will drive affordability and expand access in emerging markets
New Publish Report:
.

About the Company

Renub Research is a Market Research and Consulting Company with more than 15 years of experience, especially in international Business-to-Business Research, Surveys, and Consulting. We provide a wide range of business research solutions that help companies make better business decisions.

We partner with clients across all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele includes key players in Healthcare, Travel & Tourism, Food & Beverages, Power & Energy, Information Technology, Telecom & Internet, Chemicals, Logistics & Automotive, Consumer Goods & Retail, Building & Construction, and Agriculture.

Our core team comprises experienced professionals with graduate, postgraduate, and Ph.D. qualifications in Finance, Marketing, Human Resources, Bio-Technology, Medicine, Information Technology, Environmental Science, and more.

Media Contact

Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +91-120-421-9822 (IND) | +1-478-202-3244 (USA)
Email: rajat@renub.com
Website: www.renub.com

To explore in-depth insights, company profiles, patient trends, treatment pipelines, and regional forecasts, access the full market report:
? Global Osteoporosis Market Renub Research